紫杉醇与卡培他滨联合治疗进展期胃癌38例的临床疗效和安全性  

Clinical efficacy and security of paclitaxel combined with capecitabine in the treatment of 38 cases patients with advanced gastric cancer

作　　者：黄广清[1] 单海霞[1] 

机构地区：[1]徐州医学院附属医院肿瘤科,江苏徐州221006

出　　处：《胃肠病学和肝病学杂志》2014年第12期1413-1415,共3页Chinese Journal of Gastroenterology and Hepatology

基　　金：2014年江苏省卫生厅项目(H201323)

摘　　要：目的评价紫杉醇与卡培他滨联合治疗进展期胃癌的临床疗效及安全性。方法随机抽取徐州医学院附属医院2012年11月-2014年4月收治的进展期胃癌患者76例作为研究对象,将其分为观察组和对照组,分别给予紫杉醇联合卡培他滨治疗和紫杉醇、顺铂和5-FU联合治疗,在治疗期间对其临床疗效和毒副反应进行评估分析。结果两组患者的有效率相比,差异无统计学意义(P>0.05),而骨髓抑制和手足综合征的毒副反应相比,差异有统计学意义(P<0.05)。结论紫杉醇联合卡培他滨联合治疗进展期胃癌安全有效,患者能够耐受毒副反应,值得临床推广使用。Objective To evaluate the efficacy and security of paclitaxel combined with capecitabine in the treatment of patients with advanced gastric cancer. Methods Seventy-six cases of patients with advanced gastric cancer treated in the Affiliated Hospital of Xuzhou Medical College from Nov. 2012 to Apr. 2014 were randomly admitted for the study. They were divided into two groups and separately given the treatment of paclitaxel combined with capecitabine and the therapy of paclitaxel, cis-platinum and 5-FU. During the treatment, the clinical treatment and toxicity would be analyzed and evaluated. Results There was no statistical difference of the efficacy between two groups （P 〉 0.05） , while the toxicity of bone marrow suppression and hand-foot syndrome toxicity between two groups showed a significant difference （P 〈 0.05）. Conclusion The treatment of paclitaxel combined with capecitabine for advanced gastric cancer is safe and effective, and the patients could tolerate the side effects. It is worthy of clinical application.

关 键 词：紫杉醇 卡培他滨 进展期胃癌 临床疗效 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]